JOURNAL OF THE LOUISIANA STATE MEDICAL SOCIETY
REFERENCES
tumor responses with pembrolizumab (anti-PD-1) in melanoma. N Engl J Med . 2013;369:134–44. 24. Daud A, Ribas A, Robert C, Hodi FS,Wolchok JD, Joshua AM, et al. Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001. J Clin Oncol . 2015;33: 25. Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab- refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16:908–18. 26. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521–32. 27. Curran MA, MontalvoW, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci 2010;107:4275–80. 28. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122–33. 29. PostowMA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med . 2015;372:2006–17. 30. Ibrahim RA, Berman DB, de Pril V, et al. Ipilimumab safety profile: summary of findings from completed trials in advanced melanoma. J Clin Oncol 2011;29 Dr. Desai is a third-year fellow at the LSUHSC in the Section of Hematology/Oncology; A. Myers is a second-year medical student at the LSU School of Medicine, New Orleans; Dr. Boulmay is an Associate Professor in the Section of Hematology/Oncology at LSUHSC-New Orleans; Dr. Lopez is the Richard Vial Professor and Vice Chair in the Department of Medicine at LSUHSC- New Orleans, LA.
1. “SEER Stat Fact Sheets: Melanoma of the Skin” National Cancer Institute Surveillance, Epidemiology, and End Results Program. Accessed Sept 28, 2016. 2. Lejeune FJ. The conquest of melanoma by immunotherapy. Melanoma Res . 2015 Oct;25(5):373-5. 3. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18:158–66. 4. Maverakis E, Cornelius LA, Bowen GM, Phan T, Patel FB, Fitzmaurice S, He Y, Burrall B, Duong C, Kloxin AM, Sultani H, Wilken R, Martinez SR, Patel F. Metastatic melanoma - a review of current and future treatment options. Acta Derm Venereol . 2015 May; 95(5):516-24. 5. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am. 2000 Feb; 6 Suppl 1:S11-4. 6. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-16. 7. Flaherty K., Infante J., Daud A., Gonzalez R., Kefford R., Sosman J., et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Eng J Med 367: 2012 1694–1703. 8. Hill G, Krementz E, Hill H: Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. Cancer . 1984, 53: 1299-1305. 9. Phan G, Attia P, Steinberg S, White D: Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. Journal of Clinical Oncology. 2001, 19 (15): 3477-3482. 10. Atkins M, Lotze M, Dutcher J, Fisher R: High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. Journal of Clinical Oncology. 1999, 17 (7): 2105-2116. 11. Harlin H, Kuna TV, Peterson AC, Meng Y, Gajewski TF. Tumor progression despitemassive influx of activated CD8(+) T cells in a patient withmalignant melanoma ascites. Cancer Immunol Immunother . 2006;55:1185–97. 12. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science. 2008;322:271–5. 13. Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L: Immunostimulatory monoclonal antibodies for cancer therapy. Nature reviews Cancer . 2007, 7 (2): 95-106. 14. Robert C, Thomas L, Bondarenko I, O’Day S, MDJ, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, et al: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med . 2011, 364 (26): 2517-2526. 15. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363 (8): 711-723. 16. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33:1889–4. 17. Spranger S, Spaapen RM, ZhaY,Williams J, MengY, HaTT, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells Sci Transl Med . 2013 Aug 28; 5(200): 200ra116. 18. Okazaki T, Honjo T: The PD-1-PD-L pathway in immunological tolerance. Trends Immunol . 2006, 27 (4): 195-201. 19. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, SharfmanWH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020– 30. 20. Hodi, et al. 2016 American Association for Cancer Research (AACR) Annual Meeting. 21. Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumabversus chemotherapy inpatientswithadvancedmelanomawho progressed after anti-CTLA-4 treatment (CheckMate 037): a randomized, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16:375–84. 22. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med . 2015;373:23–34. 23. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and
82 J La State Med Soc VOL 169 MAY/JUNE 2017
Made with FlippingBook Digital Publishing Software